Publication
Rituximab-Conjugated DART Nanoformulation for CD20-Targeted Drug Delivery in Non-Hodgkin Lymphoma.
Md Musavvir Mahmud, Byoungjae Kong, Daiheon Lee, Eduar Fernando Pinzon Burgos, Alonso Heredia, Jung Soo Suk, Anthony J Kim
International journal of nanomedicineJan 1, 2026PMID 42764913doi:10.2147/IJN.S625158 PMC13589995Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
INTRODUCTION: To develop rituximab (RTX)-conjugated decreased nonspecific adhesivity receptor-targeted (DART) nanoparticles for CD20-targeted paclitaxel (PTX) delivery in non-Hodgkin lymphoma (NHL) and evaluate their targeting, therapeutic activity, formulation stability, and immune-associated…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerNon-Hodgkin Lymphomadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.